Five years ago, patients with late-stage melanoma that had spread to other organs had no good treatment options. 

A pair of treatment breakthroughs changed that in 2011.

The first immunotherapy drug of its type, which freed the immune system to attack melanoma, and the first drug to hit a specific target on melanoma cells were approved by the U.S. Food and Drug Administration for stage IV melanoma.

Both extend...